Management of glioblastoma in elderly patients

Jacob S. Young; Steven J. Chmura; Derek A. Wainwright; Bakhtiar Yamini; Katherine B. Peters; Rimas V. Lukas

doi:10.1016/j.jns.2017.07.048

Management of glioblastoma in elderly patients

Jacob S. Young, Steven J. Chmura, Derek A. Wainwright, Bakhtiar Yamini, Katherine B. Peters, Rimas V. Lukas^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55 years of age. The median age of diagnosis for patients with GBM is 64 years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.

Original language	English (US)
Pages (from-to)	250-255
Number of pages	6
Journal	Journal of the Neurological Sciences
Volume	380
DOIs	https://doi.org/10.1016/j.jns.2017.07.048
State	Published - Sep 15 2017

Keywords

Chemotherapy
Elderly
Geriatric
Glioblastoma
High-grade glioma
Radiation therapy
Surgical resection

ASJC Scopus subject areas

Clinical Neurology
Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jns.2017.07.048

Cite this

@article{6cbc1d25ac1245d88b23c9541078e51f,

title = "Management of glioblastoma in elderly patients",

abstract = "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55 years of age. The median age of diagnosis for patients with GBM is 64 years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.",

keywords = "Chemotherapy, Elderly, Geriatric, Glioblastoma, High-grade glioma, Radiation therapy, Surgical resection",

author = "Young, {Jacob S.} and Chmura, {Steven J.} and Wainwright, {Derek A.} and Bakhtiar Yamini and Peters, {Katherine B.} and Lukas, {Rimas V.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = sep,

day = "15",

doi = "10.1016/j.jns.2017.07.048",

language = "English (US)",

volume = "380",

pages = "250--255",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Management of glioblastoma in elderly patients

AU - Young, Jacob S.

AU - Chmura, Steven J.

AU - Wainwright, Derek A.

AU - Yamini, Bakhtiar

AU - Peters, Katherine B.

AU - Lukas, Rimas V.

PY - 2017/9/15

Y1 - 2017/9/15

N2 - Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55 years of age. The median age of diagnosis for patients with GBM is 64 years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.

AB - Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55 years of age. The median age of diagnosis for patients with GBM is 64 years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.

KW - Chemotherapy

KW - Elderly

KW - Geriatric

KW - Glioblastoma

KW - High-grade glioma

KW - Radiation therapy

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=85026852206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026852206&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.07.048

DO - 10.1016/j.jns.2017.07.048

M3 - Review article

C2 - 28870580

AN - SCOPUS:85026852206

SN - 0022-510X

VL - 380

SP - 250

EP - 255

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

ER -

Management of glioblastoma in elderly patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this